A-kinase anchoring protein 17B, pseudogeneGenealiases: AKAP16B · AKAP16BP
Q-omics provides the consensus-scored AKAP17BP profile across patient tissues and cancer cell-line models. AKAP17BP expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, AKAP17BP is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, AKAP17BP RNA expression shows 11,340 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, KIRC, and THYM as cancer lineages where AKAP17BP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AKAP17BP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AKAP17BP survival associations across molecular data types. AKAP17BP RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AKAP17BP RNA expression–survival associations across cancer types. High AKAP17BP expression shows unfavorable associations in KICH, LUSC, COAD, UVM and MESO, but favorable associations in UCS. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for AKAP17BP RNA expression.
This table summarizes AKAP17BP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for AKAP17BP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AKAP17BP shows lower tumor expression in BLCA, THCA and READ and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher AKAP17BP RNA expression in tumor versus normal tissue (log2 FC = +0.019, t-test p = .016).
This table shows molecular features associated with AKAP17BP in patient tissues and cancer cell lines. In patient samples, AKAP17BP shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
